When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

KALW's call-in show: Politics and culture, dialogue and debate. January 8, 2026 • This year, we'll spend more time on positive topics, like universal childcare in New Mexico and groups doing important ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

We celebrate 15 years of Delayed Gratification with Rob Orchard. Plus: Chris Harrigan of new Australian title The Story and speak with the head of editorial content for GQ France, Claire Hazan. Paris ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Santa Claus may be the busiest man on Christmas; however, he's still taking time out of his schedule to talk to all children, even the naughty ones. In addition to mall visits and responding to ...

Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, insurance portfolio management, finance and accounting, personal investment and financial ...